Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer
JCO Precision Oncology · 2024-02 · (8)
DOI: 10.1200/po.23.00127 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-02. Verfasst von Oluwadunni E Emiloju und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Cell-Free Nucleic Acids, Colorectal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS.
Abstract (Originalsprache)
PURPOSE Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA). Here, we examined the pattern of use of a tumor-informed ctDNA assay in CRC MRD monitoring in routine clinical practice at Mayo Clinic, Rochester. METHODS We conducted a retrospective analysis of health records of patients with CRC who had at least one tumor-informed ctDNA assay from May 2019 through July 1, 2022. Recurrence was defined as radiographic evidence of disease. Descriptive characteristics of the cohort, ctDNA results, and subsequent interventions were recorded. RESULTS Of the 120 patients included, the median age at diagnosis was 67 years, 46% were female, and 94% were White. At diagnosis, 10 patients had stage I, 23 stage II, 60 stage III, and 25 stage IV disease. Of 476 ctDNA assays performed, 70% were performed in patients who had recurrent disease most commonly to monitor the effectiveness of therapeutic interventions and 16% resulted in a change in clinical decision making. There were 110 recurrences identified in 62 patients, as some patients experienced more than one recurrence over time. Compared with serum carcinoembryonic antigen levels, ctDNA results correlated better with radiologic imaging. CONCLUSION Routine ctDNA monitoring for MRD detection has been adopted in clinical practice; however, 84% of ctDNA assays performed did not result in a change in clinical management. This suggests the need for further clinical research data to guide routine clinical use of ctDNA MRD testing in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Mayo Clinic, Rochester, MN.
- Department of Medicine, Mayo Clinic, Rochester, MN.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
- Department of Hematology and Oncology, University Hospitals, Cleveland, OH.
- Department of Surgery, Mayo Clinic, Rochester, MN.
ORCID-Profile: Oluwadunni E Emiloju, Nguyen Tran, Krishan Jethwa, Amit Mahipal, Jessica Mitchell, Cornelius Thiels, Robert McWilliams, Joleen Hubbard, Frank Sinicrope, Qian Shi, Zhaohui Jin
Förderung
- NIMHD NIH HHS
Zitieren
APA
Emiloju, O. E., Storandt, M., Zemla, T., Tran, N., Jethwa, K., Mahipal, A., Mitchell, J., Thiels, C., Mathis, K., McWilliams, R., Hubbard, J., Sinicrope, F., Shi, Q., & Jin, Z. (2024). Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00127
Vancouver
Emiloju OE, Storandt M, Zemla T, Tran N, Jethwa K, Mahipal A, et al. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.23.00127
BibTeX
@article{Emiloju2024,
author = {Emiloju, Oluwadunni E and Storandt, Michael and Zemla, Tyler and Tran, Nguyen and Jethwa, Krishan and Mahipal, Amit and Mitchell, Jessica and Thiels, Cornelius and Mathis, Kellie and McWilliams, Robert and Hubbard, Joleen and Sinicrope, Frank and Shi, Qian and Jin, Zhaohui},
title = {Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po.23.00127}
}
EUVIMED